YOLFTbeta
Neuroscientific Biopharmaceuticals Ltd

Neuroscientific Biopharmaceuticals Ltd

NSB · AU · Healthcare / Biotechnology

0.054AUD+0.00 (+3.85%)

Price History

Full chart

Market Stats

Previous Close0.052
Open0.058
Day Range0.052 – 0.058
52-Week Range0.055 – 0.18
Volume209.53K
Market Cap24.16M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta1.23
50-Day Avg0.0617
200-Day Avg0.0899

About

NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Nathan Smith
  • Employees0
  • Headquarters216 St Georges Terrace, Perth, WA, Australia, 6000, Australia
  • Websitehttps://www.neuroscientific.com

Leadership

  • Mr. Nathan SmithChief Executive Officer
  • Dr. Marian SturmChief Scientific Officer
  • Dr. Catherine Cole MBBSChief Medical Officer
  • Mr. Christopher Bryan James Achurch B.Com., C.A.Company Secretary

Financials

Income Statement

Currency: AUD2015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue1.19K116.00K38.02K28.88K33.85K76.27K958.77K68.45K4.95M2.21M166.08K-
Growth (%)-+9647.90%-67.22%-24.06%+17.22%+125.32%+1157.07%-92.86%+7135.94%-55.34%-92.49%-
Cost of Revenue--9.89K42.98K55.20K56.66K61.41K64.92K57.85K91.34K4731.38M
Gross Profit-116.00K28.13K-14.11K-21.36K-56.66K897.36K-64.92K-57.85K-91.34K-92.78K-1.38M
Gross Margin-100.00%73.99%-48.85%-63.09%-74.29%93.60%-94.84%-1.17%-4.13%-55.86%-
Operating Expense-335.00K326.86K946.61K1.63M2.88M5.12M10.44M6.07M1.97M1.82M3.72M
Operating Income-271.00K-219.00K-298.72K-960.71K-1.65M-2.94M-4.22M-10.50M-6.12M-2.06M-1.92M-5.11M
Operating Margin-22773.11%-188.79%-785.60%-3327.03%-4880.50%-3856.04%-440.56%-15345.51%-123.65%-93.00%-1154.44%-
EBITDA-270.00K-319-288.67K-917.19K-1.60M-2.81M-3.12M-10.37M-5.96M-1.80M-1.92M-3.72M
EBITDA Margin-22689.08%-0.27%-759.16%-3176.30%-4715.06%-3686.90%-325.00%-15149.74%-120.41%-81.20%-1153.87%-
Net Income-270.00K-103.00K-261.12K-931.42K-1.66M-2.87M-3.18M-10.44M-1.07M324.21K-1.85M-4.69M
Net Income Margin-22689.08%-88.79%-686.70%-3225.59%-4901.18%-3761.64%-331.47%-15244.70%-21.58%14.66%-1111.22%-
R&D-232.80K232.80K75.52K730.42K1.42M2.22M7.22M4.03M492.46K128.73K1.08M
R&D as % of Total Revenue-200.69%612.24%261.52%2157.88%1865.74%231.34%10547.85%81.28%22.26%77.51%-
Interest Expense37534457812503.42K6368.45K4.73K10.00K2.46K3.67K
Interest Expense % of Total Revenue31.51%0.30%1.52%0.43%0.00%4.48%0.01%100.00%0.10%0.45%1.48%-

Balance Sheet

Currency: AUD2015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets-246.58K578.94K808.90K5.12M3.74M14.83M7.74M5.29M5.44M16.96M15.18M
Total Liabilities-122.12K43.15K76.39K62.48K88.53K223.41K2.22M597.36K85.68K149.22K374.89K
Total Equity-124.47K535.79K732.52K5.06M3.65M14.60M5.52M4.69M5.35M16.81M14.81M
Cash62.54K4.79K125.81K103.89K4.61M3.29M14.16M7.22M4.91M4.95M7.27M2.63M
Total Debt-----------87.04K
Net Debt--4.79K-125.81K-103.89K-4.61M-3.29M-14.16M-7.22M-4.91M-4.95M-7.27M-2.54M

Cash Flow

Currency: AUD2016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-87.76K-186.42K-497.91K-1.41M-2.28M-2.60M-6.94M-2.30M44.25K-941.33K-2.61M
Investing Cash Flow-10.00K-15.00K-19.08K-19.08K-2.38K-29.88K-3.87K0-1.81K-36.04K-2.00M
Financing Cash Flow40.00K322.44K476.00K5.93M960.80K13.51M0003.29M-30.26K
Capital Expenditure10.00K15.00K19.08K19.08K2.38K29.88K3.87K01.81K02.61M
Free Cash Flow-97.76K-201.42K-497.91K-1.43M-2.28M-2.63M-6.95M-2.30M42.43K-941.33K-2.78M
FCF to OCF111.40%108.05%100.00%101.36%100.10%101.15%100.06%100.00%95.90%100.00%106.62%

Earnings

Report DateMay 30, 2018Jul 25, 2018Feb 25, 2019Aug 30, 2019Feb 27, 2020Sep 1, 2020Feb 23, 2021Aug 27, 2021Feb 27, 2022Aug 30, 2022Feb 28, 2023Feb 26, 2025Aug 27, 2025
EPS Estimate0.000.000.000.000.000.000.00-0.00--0.00-
EPS Actual0.00-0.01-0.02-0.01-0.02-0.01-0.02-0.01-0.04-0.03-0.020.00-0.01
Surprise-------------
Timing--------After-hoursPre-marketAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap24.16M
Enterprise Value19.23M
Trailing P/E0.00
Forward P/E0.00
Price / Sales60.01
Price / Book1.61
EPS-0.01
Book Value0.038
Revenue (TTM)402.66K
Gross Profit (TTM)258.28K
EBITDA-3.32M
Profit Margin0.00%
Operating Margin-3407.53%
Return on Equity-29.68%
Return on Assets-18.30%
Shares Outstanding389.72M
Shares Float183.67M
Beta1.23
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%